Led · Equity · Mar 2022

Fisher Wallace manufactures the Fisher Wallace Stimulator®, a patented, FDA‑cleared prescription wearable brain stimulation device for depression, anxiety and insomnia. The device was scientifically validated in randomized clinical trials during the pandemic and is advertised as causing no serious side effects and usable alongside medication or talk therapy. The company reports a user base of over 85,000 patients and an out‑of‑pocket price point of $499. Fisher Wallace plans Version 2.0 hardware for release in 2023 and is developing its first mobile app to pair with the new device. Design partners for Version 2.0 include industrial designer Eric Fields and Alloy Product Development. Proceeds from recent financings will fund additional research, Version 2.0 product development, and the company’s growth strategy.